New preprint: Deciphering bedaquiline and clofazimine resistance in tuberculosis Philip Fowler, 22nd March 202122nd March 2021 0 shares In this preprint we examine 14,151 clinical isolates drawn from the CRyPTIC dataset. Each isolate had its minimum inhibitory concentration (MIC) to bedaquiline and clofazimine measured and hence we were able to identify the transcription regulator Rv0678, as the current main source of elevated MICs to both these drugs. Lindsay Sonnenkalb, who is studying for her PhD with Stefan Niemann, then evolved Mycobacterium tuberculosis strains under sub-lethal concentrations of both compounds and was able to identify 189 different Rv0678 genetic variants that confer elevated MICs to bedaquiline and clofazimine. Detailed modelling of the protein structure allowed us to posit four main resistance mechanisms: impairment of DNA binding, reduction in protein stability, disruption of protein dimerization, and reduction in affinity for its fatty acid ligand. Share this:Twitter Related antimicrobial resistance clinical microbiology publication
antimicrobial resistance New paper: predicting pyrazinamide resistance 20th March 202420th March 2024 This paper has finally been published and you can find it here. It had a… Share this:Twitter Read More
New publication: CRyPTIC Data Compendium 16th August 202216th August 2022 The large and comprehensive dataset of clinical tuberculosis isolates collected by the CRyPTIC project is… Share this:Twitter Read More
antimicrobial resistance Diagnosing antibiotic resistance: future trends? 23rd April 20175th August 2018 It is Sunday, I’m in Vienna at the European Congress of Clinical Microbiology and Infectious… Share this:Twitter Read More